<?xml version="1.0" encoding="UTF-8"?>
<p>On the basis of previous results, an open-label, randomized, phase 2 trial (NCT04276688) evaluated the clinical impact of the triple combination, IFN beta-1b, lopinavirâ€“ritonavir, and ribavirin [
 <xref rid="B155-jcm-09-02084" ref-type="bibr">155</xref>]. The authors showed that treatment with the triple combination therapy effectively suppressed viral load in all clinical admitted patients, in most cases, within 8 days from treatment commencement, a significantly shorter period compared with the time taken in the control group. The results also revealed that the triple combination also alleviated symptoms completely in a significantly shorter time (4 days) compared with the control and suppressed IL-6 levels [
 <xref rid="B155-jcm-09-02084" ref-type="bibr">155</xref>].
</p>
